02 December 2020: Clinical Research
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China
Shuang Huang C* , Changxin Shen B* , Chengliang Xia F , Xiaoxing Huang C , Yourong Fu A , Li Tian E*DOI: 10.12659/MSM.928755
Med Sci Monit 2020; 26:e928755
Table 2 Other supportive treatments given to the 24 patients with COVID-19 pneumonia who were treated with COVID-19 convalescent plasma during February and March 2020 at 2 centers in Wuhan, China.
| Patient no. | Respiratory support | Antiviral therapy | Antibiotics or antifungal therapy | Corticosteroids therapy |
|---|---|---|---|---|
| 1 | IPPV | Arbidol 0.2 g q8h po. | Tigecycline i.v., polymyxin B i.v. | None |
| 2 | HFNC+NPPV | Lopinavir and Ritonavir Tablets (Take 3 tablets twice a day) | Cefoperazone Sodium and Sulbactam Sodium i.v., polymyxin B i.v. Voriconazole i.v. | Methylprednisolone i.v. |
| 3 | HFNC+NPPV | Arbidol 0.2 g q8h po. | Moxifloxacin i.v., Voriconazole i.v. | Methylprednisolone i.v. |
| 4 | IPPV+ECMO | Arbidol 0.2 g q8h po. | Imipenem i.v., Linezolid i.v. | None |
| 5 | HFNC | Arbidol 0.2 g q8h po.IFN-α 500 MIU qd inh. | Moxifloxacin i.v., Cefoperazone Sodium and Sulbactam Sodium i.v. | Methylprednisolone i.v. |
| 6 | IPPV+ECMO | Arbidol 0.2 g q8h po. | Imipenem-Sitastatin Sodium i.v., Cefoperazone Sodium and Sulbactam Sodium i.v., Caspofungin i.v. | None |
| 7 | HFNC | Lopinavir and Ritonavir Tablets (Take 3 tablets twice a day) | Moxiflxacin i.v., Imipenem-Sitastatin Sodium i.v. | Methylprednisolone i.v. |
| 8 | HFNC | Arbidol 0.2 g q8h po. | Imipenem-Sitastatin Sodium i.v., Cefoperazone Sodium and Sulbactam Sodium i.v. | Methylprednisolone i.v. |
| 9 | IPPV | Arbidol 0.2 g q8h po. | Levofloxaxin i.v., Cefoperazone Sodium and Sulbactam Sodium i.v., Moxiflxacin i.v. | None |
| 10 | IPPV | Arbidol 0.2 g q8h po. | Moxiflxacin i.v., Imipenem i.v., Linezolid i.v. | None |
| 11 | IPPV | Arbidol 0.2 g q8h po.Ribavirin 0.5 g qd i.v. | Moxiflxacin i.v., Cefoperazone Sodium and Sulbactam Sodium i.v. | Methylprednisolone i.v. |
| 12 | HFNC | Arbidol 0.2 g q8h po. | Moxiflxacin i.v., Cefoperazone Sodium and Sulbactam Sodium i.v. | None |
| 13 | LFNC | Ribavirin 0.5 g qd i.v.IFN-α 500 MIU qd inh. | Moxiflxacin i.v., Levofloxaxin i.v. | Methylprednisolone i.v. |
| 14 | IPPV+ECMO | Ribavirin 0.5 g qd i.v. | Imipenem-Sitastatin Sodium i.v., Linezolid i.v. | Methylprednisolone i.v. |
| 15 | HFNC | Arbidol 0.2 g q8h po.IFN-α 500MIU qd inh. | Moxiflxacin i.v., Cefoperazone Sodium and Sulbactam Sodium i.v. | Methylprednisolone i.v. |
| 16 | IPPV+ECMO | Arbidol 0.2 g q8h po. | Moxiflxacin i.v., Imipenem i.v., Tigecycline i.v. | Methylprednisolone i.v. |
| 17 | HFNC | Arbidol 0.2 g q8h po. | Moxiflxacin i.v. | None |
| 18 | LFNC | Arbidol 0.2 g q8h po.Lopinavir and Ritonavir Tablets (Take 3 tablets twice a day) | Piperacillin Sodium and Tazobactam Sodium i.v. | Methylprednisolone i.v. |
| 19 | LFNC | Arbidol 0.2 g q8h po. | Moxiflxacin i.v. | Methylprednisolone i.v. |
| 20 | HFNC | Ribavirin 0.5 g qd i.v. | Moxiflxacin i.v., Imipenem-Sitastatin Sodium i.v. | None |
| 21 | IPPV | Arbidol 0.2 g q8h po. | Tegacycline i.v., Imipenem i.v. | None |
| 22 | HFNC | Arbidol 0.2 g q8h po.Ribavirin 0.5 g qd i.v.IFN-α 500MIU qd inh. | Moxiflxacin i.v., Imipenem-Sitastatin Sodium i.v. | Methylprednisolone i.v. |
| 23 | HFNC | Lopinavir and Ritonavir Tablets (Take 3 tablets twice a day) | Piperacillin Sodium and Tazobactam Sodium i.v. | None |
| 24 | HFNC | Arbidol 0.2 g q8h po. | Moxiflxacin i.v. | None |
| IPPV – Intermittent positive pressure ventilation; HFNC – high-flow nasal cannula; NPPV – noninvasive positive pressure ventilation; ECMO – extracorporeal membrane oxygenation; LFNC – low-flow nasal cannula; q8h – every 8 h; po. – per os; MIU – million IU; qd – every day; inh. – inhalation; i.v. – injection. | ||||